iPhone App HEP I-chart for Hepatitis C Treatment Launched by Liverpool Varsity

An iPhone app, HEP i-chart, which provides Hepatitis C (HCV) patients with quick and simple access to the latest information on drug interactions, was launched by UK-based University of Liverpool.

Hepatitis C was first discovered in the 1980s when it became apparent that there was a new virus (not the already known hepatitis A or B) causing liver damage. Hepatitis C causes inflammation and swelling of the liver.

Hepatitis C - Causes, Symptoms, Diagnosis, Treatment, Complications, Prevention
Hepatitis C is a contagious viral disease affecting the liver that is caused by the hepatitis C virus.

It is estimated that over 170 million individuals - representing 3% of the world's population - are chronically infected with the Hepatitis C virus (HCV). Statistically, as many people are infected with HCV as are with HIV.

Since its identification, drug treatment to eradicate the virus has advanced greatly, especially in the last few years. Two new drugs have recently been licensed for treatment of HCV, and there are more drugs in development.

HEP i-chart developed at the University by Professor David Back and Professor Saye Khoo which provides a comprehensive online guide to the interactions between anti-hepatitis drugs and other drugs.

HCV Positive Kidney Failure Patients Can Receive Kidneys from HCV Positive Donors
Study shows that kidney donation among HCV sero-positve donors and recipients is possible and can cut down on the “waiting list” for patients awaiting transplantation.

It is a tool that provides Hepatitis C patients and healthcare professionals with immediate access to up-to-date information on potential drug interactions between HCV drugs, and other drugs that the patient may be prescribed as well as over-the-counter, recreational or herbal medications.

Existing HCV drugs, newly licensed drugs and drugs in development can have interactions with each other and with other drugs which can impact on their effectiveness - sometimes with serious consequences. For this reason, some drug combinations must not be used, whilst others must be given with caution, possibly requiring adjustment or monitoring.

Rebound of Hepatitis C Virus in Liver Transplant Patients Prevented by Experimental Drug
A human monoclonal antibody that was given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus

Professor of Pharmacology, David Back, said: "We are delighted to launch with our partners - KnowledgePoint360, MSD and Janssen- this new i-phone application that provides Hepatitis C patients and healthcare professionals with instant and easy access to information about HCV drug interactions which is relevant and reliable and up-to-date. This resource is especially important as new HCV drug treatments are approved and come into use."

Professor Graham Foster, President of the British Association for the Study of the Liver (BASL) said: "This new app, HEP i-chart, is a timely and much-needed resource for HCV patients as the number of new drugs which are available to treat Hepatitis C increases."

How to Prevent Hepatitis C Virus After a Liver Transplant
Liver failure or liver cancer caused by liver cell infection with hepatitis C virus (HCV) happen to be the most common causes that require liver transplantation.

Source-ANI